TTF-1 monoclonal comparison

scoring(0: no expression or faint expression of <5% of the tumor nuclei, 1: when faint expression of >=5% of the tumor nuclei, 2: when bright expression of >=5% of the tumor nuclei. 1 and 2 were considered as positive staining.)

SPT24 (from Novocastra)

8G7G3/1 (from Dako)

BGX-397A

Pulmonary small cell carcinoma

7/84, 16/199  

7/84, 14/199  

Pulmonary  carcinoid

14/23(using TMA)8

4/23(using TMA)8

Pulmonary atypical carcinoid

5/54, 2/10(1/9 central, 1/1 peripheral)9  

2/54, 0/10(0/9 central, 0/1 peripheral)9  

Pulmonary typical carcinoid

5/114, 15/41(7/30 central, 8/11 peripheral)9  

1/114, 4/41(0/30 central, 4/11 peripheral)9  

Primary pulmonary adenocarcinoma

72/861, 12/174, 134/185(using TMA)8

56/86(all positive cases were also positive with SPT24. 13 cases with a score of "1" scored "2" using SPT24)1, 11/174, 121/185(using TMA)8

Pulmonary large cell carcinoma

6/124, 22/47(using TMA)8

5/124, 17/47(using TMA)8

Pulmonary large cell neuroendocrine carcinoma

10/13(9/12 central, 1/1 peripheral)9  

4/13(4/12 central, 0/1 peripheral)9  

Pulmonary squamous cell carcinoma

2/144, 14/97(using TMA)8

1/144, 1/97(using TMA)8

Pulmonary carcinoma unclassified

10/22(using TMA)8

7/22(using TMA)8

Squamous cell carcinoma of head and neck

0/38(using TMA)8

0/38(using TMA)8

Salivary gland

1/56(using TMA)8

1/56(using TMA)8

Gastric adenocarcinoma

1/12(in three additional cases, < 10% of neoplastic cells stained)4, 1/110(using TMA)8

0/12(in one case, < 10% of neoplastic cells stained, a cytoplasmic reaction was occasionally seen in the neoplastic cells)4, 1/110(using TMA)8  

Primary colorectal carcinoma

4/90(using tissue microarrays: the positive cases showed staining of 20-40~% of nuclei, often associated with cytoplasmic staining.)1, 3/6(three cases showed focal positivity)2, 1/17(in one additional case, <10% of neoplastic cells stained)4, 3/120(using TMA)8

0/901, 0/62, 0/174, 3/120(using TMA)8

Lung metastases from primary colorectal adenocarcinoma

4/41(Staining was seen in 10-40% of the nuclei of the positive cases. In two cases, nuclear staining was associated with cytoplasmic staining. All had documented colorectal primaries, with lung metastases showing the typical morphology of colorectal metastases and all CK7-/CK20+. In all three cases where suitable material was available, extra-pulmonary tumour was also TTF-1 positive.)1

0/41(both primaries and lung metastases were negative. One case showed very faint nuclear graying, below the threshold for positivity.)1

Nodal metastasis from colorectal carcinoma

1(case report: also positive in primary tumour: staining was stronger than for 8G7G3/1)3

1(case report: also positive in primary tumour)3

Liver metastasis from colorectal carcinoma

1(case report: staining was stronger than for 8G7G3/1)3

1(case report)3

Lung metastases from renal carcinoma

0/61

0/61

Gastric carcinoid

0/69

0/69

Intestinal carcinoid

0/28, 0/5494

0/28(a cytoplasmic reaction was occasionally seen in the neoplastic cells)4, 0/549

Pancreatic carcinoid

0/269

0/269

non-pulmonary poorly differentiated neuroendocrine carcinoma

8/45(0/5 oesophagus, 2/8 stomach, 1/12 intestine, 2/2 pancreas, 1/1 gallbladder, 0/4 skin, 0/2 uterus, 2/6 prostate, 0/1 bladder, 0/4 head and neck)9

5/45(0/5 oesophagus, 2/8 stomach, 0/12 intestine, 0/2 pancreas, 0/1 gallbladder, 0/4 skin, 0/2 uterus, 2/6 prostate, 1/1 bladder, 0/4 head and neck)9

Pancreas adenocarcinoma

0/5(in one case, < 10% of neoplastic cells stained)4, 0/110(using TMA)8

0/54, 0/110(using TMA)8

Breast adenocarcinoma

0/144, 0/2(metastatic to lung)1, 0/34(using TMA)8

0/144, 0/2(metastatic to lung)1, 0/34(using TMA)8

Bladder, invasive urothelial carcinoma

5/98(using TMA)8

5/98(using TMA)8

Prostatic adenocarcinoma

0/84, 2/160(using TMA)8

0/8(a cytoplasmic reaction was occasionally seen in the neoplastic cells)4, 2/160(using TMA)8

Ovarian serous carcinoma

1/64, 1/20(TMA; positivity in less than 25% of nuclei in one case^b)5, 6/36(surgical specimens ; positivity in >50% of nuclei in 2 cases, 3% to 25% of nuclei in one case, < 3% in 3 cases^b)5

1/6(a cytoplasmic reaction was occasionally seen in the neoplastic cells)4, 0/20(TMA)5, 2/36(surgical specimens; positivity in >50% of nuclei in two case)5

1/20(TMA; positivity in less than 25% of nuclei in one case^b)5

Ovarian clear cell carcinoma

0/54, 2/20(TMA; positivity in 3% to 50% of nuclei in one case, positivity in 26% to 50% of nuclei in one case^b)5, 1/7(surgical specimens; positivity in less than 25% of nuclei in one case^b)5

0/54, 0/20(TMA)5, 1/7(surgical specimens; positivity in less than 3% of nuclei in one case)5

2/20(TMA; positivity in 3% to 50% of nuclei in one case, positivity in 26% to 50% of nuclei in one case^b)5

Ovarian endometrioid carcinoma

0/54, 2/20(TMA; positivity in 26% to 50% of nuclei in one cases^b)5, 0/7(surgical specimens^b)5

0/54, 1/20(TMA; positivity in 26% to 50% of nuclei in one case)5, 0/7(surgical specimens^a)5

2/20(TMA; positivity in 26% to 50% of nuclei in two cases^b)5

Ovarian mucinous carcinoma

1/20(TMA; positivity in 26% to 50% of nuclei in one case^b)5, 1/3(surgical specimens; positivity in < 25% of nuclei in one case^b)5

0/20(TMA^a)5, 0/3(surgical specimens^a)5

1/20(TMA; positivity in 26% to 50% of nuclei in one case^b)5

Ovarian poorly differentiated carcinoma

0/20(TMA^b)5

0/20(TMA^a)5

0/20(TMA^b)5

Ovarian serous cystadenoma

0/4(TMA^b)5

0/4(TMA^a)5

0/4(TMA^b)5

Ovarian mucinous cystadenoma

1/3(TMA; positivity in <25% of nuclei in one case^b)5, 0/2(surgical specimens^b)5

0/3(TMA^a)5, 0/2(surgical specimens^a)5

1/3(TMA; positivity in <25% of nuclei in one case^b)5

Ovarian malignant mixed Mullerian tumour

1/2(surgical specimens; positivity in >50% of nuclei in one case^b)5

0/2(surgical specimens^a)5

Uterine serous carcinoma

4/18(surgical specimens ; positivity in less than 25% of nuclei in four cases^b)5

1/18(surgical specimens; positivity in less than 3% of nuclei in one case^a)5

Uterine endometrioid carcinoma

4/18(surgical specimens; positivity in less than 3% of nuclei in one case, 3 to 25 % of nuclei in two cases, >50% of nuclei in one case^b)5

1/18(surgical specimens ; positivity in >50% of nuclei in one case^a)5

Uterine malignant mixed Mullerian tumour

9/11(surgical specimens; positivity in less than 3% of nuclei in four cases, 3 to 25 % of nuclei in three cases, 25% to 50% of nuclei in two cases^b)5

0/11(surgical specimens^a)5

Glioblastoma multiforme

14/28(<2% of nuclei in 7 cases, 2% to 10% of nuclei in 3 cases, over 30% of nuclei n 4 cases)6

0/286

Gliosarcoma

0/16

0/16

Comparison of TTF-1 clones and staining machines for assorted gynaecological carcinomas selected for their positivity5:

8G7G3/1

SPT24